CVA Family Office’s Kiniksa Pharmaceuticals KNSA Stock Holding History

CVA Family Office’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$895	Buy	+14	New	+$726	﹤0.01%	1660

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

CVA Family Office's KNSA Position: Q2 2026 in Review

CVA Family Office opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 14 shares worth $895. The stake represents ﹤0.01% of the portfolio and ranks #1660 among its holdings.

266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

CVA Family Office held 14 shares of Kiniksa Pharmaceuticals worth $895 as of Q2 2026.
Kiniksa Pharmaceuticals was a new CVA Family Office position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1660 holding.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.